@GeorgeGoshuaMD What happens when a patient dies from iTTP and doesn’t receive this therapy? The argument that you are on a crusade to lower drug costs will not hold legal water. Prepare for major liability
@GeorgeGoshuaMD If by “power of the prescription pad” you mean withhold this treatment, I think you are really playing with fire. You have an FDA approved therapy that likely reduces mortality and you advise withholding because of cost?
Outstanding commentary by James George, the King of TTP, on the Coppo paper of the French cohort. Can we really be looking at managing TTP without plasma exchange? If you manage patients with TTP you must read this short commentary. #TTP https://t.co/5cSc2qgpib
Is plasma exchange still needed for #TTP? A thought provoking commentary on the future of the field by Dr. James George. A must read for anyone who treats this devastating condition
Excellent study by Coppo and colleagues: triplet therapy with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated #TTP in @BloodJournal
#hemetwitter#TMA
https://t.co/IxFnZXaVrZ
How it started:
Eculizumab for the treatment of preeclampsia/HELLP syndrome. https://t.co/1UDBrsEoru
How it’s going:
Complement regulation to undo systemic harm in preeclampsia.
The CRUSH trial.
https://t.co/ijFOTIdl2j
Two national studies (UK and French) describing real-world evidence of using caplacizumab for treatment of iTTP published in @BloodJournal on the same day.
https://t.co/jgEH1nhcOU and https://t.co/je9wPokSu3
Amazing to be part of this free virtual meeting for patients today. @USTMAConsortium has come a long way since initial inception, lead by @ttpdoc and Spero Cataland. Thank you for spearheading this and for allowing us to be a part of this.
Finally, we have the up-to-date guidance document on #ADAMTS13 assays published ahead of print #OpenAccess.
International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13 https://t.co/5c7U1hJScR